Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to explore the safety and tolerability, and to compare the activity of
SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED).
Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a
two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will
be randomized to either SRX246 or Placebo treatment groups.
Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits
throughout the trial. The study results will be determined based on any changes observed over
the study period.